Venture Capital Deal Sourcing
"JRA delivered LSP with an excellent and thorough deal flow project over 18 months, in particular providing unequaled coverage of UK and Irish academic institutes' spin-outs, reviewing and highlighting quality opportunities from Seed to Series B. For a fund manager without an office in the UK, this was invaluable. I am happy to endorse the capabilities of JRA whose network is I believe unparalleled."
Joachim Rothe, Managing Partner, LSP (Life Science Partners).
"JRA delivered a very successful project aimed at introducing our company to the UK innovation community and conversely providing an introduction to key decision-makers within our organisation. The feedback following was very positive for the company. Critical to the success was JRA's extensive rolodex of good personal contacts built up over 10 years working with key players within the academic, biotech and investor community. We had a very collaborative working relationship with JRA, which was flexible and able to take on many tasks to ensure the project moved forward successfully. I am happy to endorse the capabilities of JRA. Working with Jon Rees PhD, Managing Director is a pleasure. His knowledge of the UK innovation environment is, I believe, unparalleled in the industry."
Ian Moules, Pharmaceutical Consultant and former Senior Director, Global Business Development, Takeda Pharmaceuticals.
"JRA performed a 4 week due diligence project for a seed investment opportunity in the drug discovery space. The value-add was significant with the written report, and face-to-face discussions, providing a detailed review of both the market landscape and the underlying science. This was helpful to identify any early red flags for the investment, but more importantly provided key topics for further dialogue with the company. I will definitely be using JRA again for future research projects and would recommend their services to other early-stage life sciences investors."
Active Angel Investor
Access to Capital
"Jon Rees is one of the very best introducers in the industry. At an investment event Jon made a special point of identifying Illumina as a potential investor in Desktop Genetics, engineering a later personal introduction of Desktop Genetics founders to an Illumina Ventures director at another investment event within a few weeks. The introduction resulted in Illumina making a strategic investment in DeskGen which we believe will be a start to some mutually beneficial collaborations and a great endorsement within the industry for DeskGen. Thank you Jon"
Michael Martin, Partner at Anvil Partners LLP